Amgen and AstraZeneca have announced that the experimental monoclonal antibody tezepelumab demonstrated a clinically meaningful reduction in annualized asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients. In the NAVIGATOR Phase 3 trial, the drug led to a 56% reduction in AAER versus placebo over 52 weeks when used as part of the standard of…
Amgen Q3 revenues up 12% — but growth questions remain
Amgen (NSDQ:AMGN) announced third-quarter earnings per share of $4.37, beating the consensus forecast of $3.80. Biosimilars growth and a strong base business drove growth in the quarter ending on Sept. 30. The company has been relatively steady in 2020, growing 11% in the first quarter and 6% in the second. “Our performance in the third quarter…